Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2020-04-28 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
公司章程（2020年4月修订）
Governance Information Classification · 95% confidence The document is a detailed company charter or articles of association for 百奥泰生物制药股份有限公司 (Bio-Thera Solutions, Ltd.). It includes chapters on general provisions, business scope, shares issuance and transfer, shareholders and shareholders' meetings, board of directors, senior management, supervisory board, financial and audit matters, notices and announcements, mergers, disputes resolution, and amendments to the charter. The content is focused on governance structure, shareholder rights, board responsibilities, and procedural rules for meetings and capital changes. There is no indication of financial statements, audit opinions, earnings data, or event announcements. The document is a governance and organizational framework document, which aligns with the definition of Governance Information (CGR). It is not an announcement or a report publication, but the actual governance document itself. Therefore, the correct classification is CGR with high confidence.
2020-04-28 Chinese
2020年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2020 年第一季度报告" which translates to "2020 First Quarter Report". It contains detailed financial data including balance sheets, profit and loss statements, cash flow analysis, and management commentary for the first quarter of 2020. The report is unaudited and covers a period shorter than a full fiscal year, consistent with an interim or quarterly report. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is the actual report, not just an announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2020
2020-04-28 Chinese
关于聘任公司证券事务代表的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a securities affairs representative (a company officer) by the board of directors. It includes details about the individual's qualifications, contact information, and compliance with regulatory requirements. There is no financial data, no report or presentation, and no mention of voting results or dividends. This fits the category of Board/Management Information (MANG), which covers announcements of changes in senior management or board members.
2020-04-28 Chinese
独立董事关于公司对外担保情况的专项说明
Regulatory Filings Classification · 95% confidence The document is a special statement by independent directors regarding the company's external guarantees for the fiscal year 2019. It references regulatory notices from the China Securities Regulatory Commission and confirms that no external guarantees occurred during the reporting period. The document is a formal attestation or certification by independent directors rather than a full audit report or financial statement. It is short (962 characters) and serves as a regulatory compliance statement rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS), which covers officer certifications and compliance documents that do not constitute full reports.
2020-04-28 Chinese
非经营性资金占用专项鉴证报告
Audit Report / Information Classification · 95% confidence The document is a special explanatory statement regarding non-operating fund occupation and other related party fund transactions for the year 2019 of 百奥泰生物制药股份有限公司. It is prepared by Ernst & Young Hua Ming LLP, a certified public accounting firm, and references audited financial statements for the year ending December 31, 2019. The document includes detailed financial data and tables about fund occupation and related party transactions, and it is explicitly described as a "special explanation" based on audited financial data. It is not a full annual report (10-K), nor is it a general audit report (AR) since it focuses on a specific issue related to non-operating fund occupation and related party transactions. It is not a short announcement or certification but contains substantive financial data and analysis related to the company's financials for a specific period. This type of document is best classified as an Audit Report / Information (AR) because it is a standalone audit-related report focusing on a specific financial issue, prepared by auditors, and separate from the full annual report. FY 2019
2020-04-28 Chinese
2019年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as "2019 年年度报告摘要" which translates to "2019 Annual Report Summary". It contains detailed financial data for the year 2019, including net profit, assets, quarterly financial data, shareholder information, and extensive discussion of business operations, risks, industry context, and company strategy. The length is about 15,000 characters, indicating a substantive report rather than a brief announcement. The content includes comprehensive financial performance and business analysis typical of an Annual Report. Therefore, this document is best classified as an Annual Report (10-K). FY 2019
2020-04-28 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.